W

WWB - Windward Bio • Price

Windward Bio Group AG is a clinical-stage biopharmaceutical company focused on the discovery, licensing, and clinical development of differentiated, ultra-long-acting biologic therapeutics targeting clinically validated immunological pathways. The company operates primarily from Basel, Switzerland, with corporate operations also established in the United States, and holds commercialization rights to its clinical-stage assets outside Greater China. Windward Bio operates in a single operating segment focused on research and drug development and is pre-revenue, having generated no commercial product sales since inception. Its pipeline is anchored by two primary clinical assets: WIN378, an ultra-long-acting fully human monoclonal antibody designed to inhibit TSLP, currently being evaluated in a Phase 2/3 study (POLARIS-1) for severe uncontrolled asthma and a Phase 2 study (SIRIUS) for COPD with a target twice-yearly subcutaneous dosing regimen; and WIN027, an investigational long-acting bispecific antibody designed to neutralize both TSLP and IL-13 simultaneously, undergoing Phase 1 evaluation with planned Phase 2 studies in COPD and atopic dermatitis. The company also maintains internal discovery research to feed its pipeline of bispecific antibodies. Windward Bio targets substantial therapeutic markets including severe asthma, COPD, and atopic dermatitis, competing against approved biologic standards of care such as tezepelumab (Tezspire) and dupilumab (Dupixent). Its competitive positioning centers on optimized molecular design aimed at substantially longer dosing intervals (e.g., semi-annual subcutaneous injections) and dual-pathway cytokine inhibition, designed to improve real-world treatment adherence and disease control.

Historical stock price chart and annual return over the past years